Jean-Charles Soria, MD, PhD, on Results of the Lux Lung 8 Clinical Trial
2015 European Cancer CongressJean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: afatinib vs erlotinib in squamous cell carcinoma of the lung.
Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: afatinib vs erlotinib in squamous cell carcinoma of the lung.
Incoming ECCO President, Peter L. J. Naredi, MD, PhD, of the University of Gothenburg, discusses his upcoming year as the new ECCO President, his vision for the organization, and his views on cancer treatment today.
Lisa Carey, MD, of the University of North Carolina, discusses heterogeneity, treatment response, and outcome in HER2-positive breast cancer.
Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: the efficacy and safety of pembrolizumab in previously treated non-small cell lung cancer (Abstract LBA33).
Cora N. Sternberg, MD, of San Camillo Forlanini Hospital, summarizes a teaching lecture on new targets in renal cell carcinoma, and discusses what to expect for the future of treating RCC.
Michael Pfreundschuh, MD, of Universitaetsklinikum des Saarlandes, summarizes a session he chaired on this topic, which covered Burkitt’s lymphoma as well as lymphoblastic leukemia in children and adults.